Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Drake, Marcus; Chapple, Christopher; Esen, Ahmet; Athanasiou, Stavros; Cambronero, Javier; Mitcheson, David; Herschorn, Sender; Saleem, Tahir; Huang, Moses; Siddiqui, Emad; Stolzel, Matthias; Herholdt, Claire; MacDiarmid, Scott

doi:10.1016/j.eururo.2016.02.030

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Copy For Citation

Drake M. J., Chapple C., Esen A. A., Athanasiou S., Cambronero J., Mitcheson D., ...More

EUROPEAN UROLOGY, vol.70, no.1, pp.136-145, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 70 Issue: 1
Publication Date: 2016
Doi Number: 10.1016/j.eururo.2016.02.030
Journal Name: EUROPEAN UROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.136-145
Keywords: Add-on therapy, Incontinence, Mirabegron, Overactive bladder, Solifenacin, QUALITY-OF-LIFE, URINARY-INCONTINENCE, NERVE-STIMULATION, IMPACT, ONABOTULINUMTOXINA, PERCEPTION, AGONIST, BURDEN
Dokuz Eylül University Affiliated: Yes

Abstract

Background: Incontinence has a greater detrimental effect on quality of life than other symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic monotherapy.